Global Biomarker of Disease Market Strategic Research Report

Scope of the Report

The global Biomarker of Disease market size is predicted to grow from US$ 36,170 million in 2025 to US$ 103,330 million in 2032; it is expected to grow at a CAGR of 16.5% from 2026 to 2032.

Omics, proteomics, meta-bolomics technologies are used in biomarkers discovery and disease diagnosis. Biomarkers are used in risk assessment, molecular diagnostic, disease diagnosis, DNA fingerprinting and other molecular applications. Biomarkers enable pharmaceutical companies to analyze and discover novel drugs as demand for cost effective and efficient treatment dose is increasing. Biomarkers are used in drug validation and testing, sample preparation and assay development to eliminate complexity in discovery and development of novel drugs. Biomarkers of disease are used in identification of disease condition and also help in validation of clinical trials for novel drug.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.

Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

This report presents a comprehensive overview of the global Biomarker of Disease market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Sample Preparation
• Assay Development
• Biomarker Validation and Testing
• Others

Segment by Application

• Pharmaceutical Companies
• Government & Private Research Institutes
• Academic Institutes
• Medical Device Manufacturing Companies
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biomarker of Disease market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical Companies, Government & Private Research Institutes, Academic Institutes evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact